BioSpace News Archive

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today announced that phase 1b study results of IBI362, a glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese participants with overweight or obesity have been published in EClinicalMedicine by the Lancet.

Alcon reported its financial results for the three and six months ended June 30, 2021.

Today Networking California for Sickle Cell Care held its inaugural meeting, marking the first time that clinicians from the ten participating Network clinics came together in one virtual “room.”

Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced a more detailed summary of the national study results announced by the Company on July 13, 2021,

MAIA Biotechnology, Inc. announced today that it has appointed Joseph F. McGuire as Chief Financial Officer. MAIA has also provided a corporate update announcing the creation of a wholly-owned subsidiary in Australia to execute on its global development strategy.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.59 billion for the third quarter ended July 31, 2021, an increase of 26% compared to the third quarter of 2020 and up 21% on a core(1) basis.

Transcenta announced that it held an investigator meeting successfully for TST001 Phase I clinical trial study on August 14.

Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany, to conduct combination studies with one of Merck KGaA, Darmstadt, Germany’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with each of Telix’s TLX591 (177Lu-rosopatamab) and TLX250 (177Lu-girentuximab) molecularly targeted radiation (MTR) therapeutic programs

Telix Pharmaceuticals Limited announces the initiation of two new investigator-led studies to evaluate the potential utility of the Company’s late-stage imaging portfolio in women’s health, initially in two sub-types of breast cancer with a significant unmet medical need.